Editorial: aspirin and NSAID for chemoprevention of hepatocellular carcinoma-ready for their use?

Aliment Pharmacol Ther. 2021 Sep;54(6):850-851. doi: 10.1111/apt.16556.

Authors

Leonardo Gomes Da Fonseca¹, Alejandro Forner^{2

3}

Affiliations

¹ Medical Oncology, Instituto do Cancer do Estado de Sao Paulo, University of Sao Paulo, Sao Paulo, Brazil.
² BCLC Group, Liver Unit, Hospital Clínic de Barcelona, Fundació Clínic per a la Recerca Biomèdica (FCRB), IDIBAPS, University of Barcelona, Barcelona, Spain.
³ Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain.

PMID: 34425013
DOI: 10.1111/apt.16556

No abstract available

Publication types

Editorial
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
Aspirin / therapeutic use
Carcinoma, Hepatocellular* / drug therapy
Carcinoma, Hepatocellular* / epidemiology
Carcinoma, Hepatocellular* / prevention & control
Chemoprevention
Humans
Liver Neoplasms* / drug therapy
Liver Neoplasms* / epidemiology
Liver Neoplasms* / prevention & control

Substances

Anti-Inflammatory Agents, Non-Steroidal
Aspirin